- Synonyms
- SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1
- Source
- Escherichia coli.
- Molecular Weight
- Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
- AA Sequence
- SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
- Purity
- > 98 % by SDS-PAGE and HPLC analyses.
- Biological Activity
- Fully biologically active when compared to standard. The ED50 as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 104 IU/mg.
- Physical Appearance
- Sterile Filtered White lyophilized (freeze-dried) powder.
- Formulation
- Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
- Endotoxin
- Less than 1 EU/μg of rHuEMAP-II as determined by LAL method.
- Reconstitution
- We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
- Stability & Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
- Usage
- This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
- SDS-PAGE
- Reference
- 1. Awasthi N, Schwarz MA, Schwarz RE. 2010. Cancer Biol Ther, 10: 99-107.
2. Journeay SandSingh B. 2007. Acta Neuropathol, 114: 435; author reply 7-8.
3. Clarijs R, Schalkwijk L, Ruiter DJ, et al. 2003. Invest Ophthalmol Vis Sci, 44: 1801-6.
4. Kayton MLandLibutti SK. 2001. Curr Opin Investig Drugs, 2: 136-8.
- Background
- Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.